Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
03/2000
03/16/2000WO2000014083A1 SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
03/16/2000WO2000014066A1 4,4-biarylpiperidine derivatives with opioid receptor activity
03/16/2000WO2000014054A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000WO2000013704A1 Formulation of nucleic acids and acemannan
03/16/2000WO2000013703A2 Methods of treating hypertension and compositions for use therein
03/16/2000WO2000013702A2 Use of an angiogenic factor for the treatment of microvascular angiopathies
03/16/2000WO2000013660A1 Lipid extract of the skeletonema algae
03/16/2000WO2000006694A3 Compound and method for the prevention and/or the treatment of allergy
03/16/2000WO2000003029A3 Chimaeric adenoviruses
03/16/2000WO2000002881A3 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
03/16/2000WO2000000216A3 Use of poxviruses as enhancer of specific immunity
03/16/2000WO1999061471A3 Human transmembrane proteins
03/16/2000CA2343536A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2343156A1 Fusion receptors specific for prostate-specific membrane antigen and uses thereof
03/16/2000CA2342898A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000CA2342882A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2342284A1 Methylation of plasmid vectors
03/16/2000CA2341338A1 G-motif oligonucleotides and uses thereof
03/16/2000CA2340686A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
03/16/2000CA2338384A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
03/16/2000CA2308444A1 Formulation of nucleic acids and acemannan
03/15/2000EP0985040A1 Preparation of glycosylated tumor necrosis factor
03/15/2000EP0984961A1 Novel pyridine derivatives and pharmaceutical compositions containing them
03/15/2000EP0984955A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS
03/15/2000EP0984692A1 Novel angiogenesis inhibitors
03/15/2000EP0649468B1 Soluble cr1 derivatives
03/15/2000EP0567566B1 Methods for treating tumor necrosis factor mediated diseases
03/15/2000EP0549702B1 Use of recombinant colony stimulating factor-1
03/15/2000EP0506785B1 Improved treatment of autoimmune diseases by aerosol administration of auto antigens
03/15/2000EP0434721B1 Viral nucleotide sequences
03/15/2000CN1247472A Treatment of lupus nephritis with anti-CD40L compounds
03/15/2000CN1247191A Imidazolium compound as synthetic material of imidazole lipoxidase inhibitor
03/15/2000CN1050364C 7-glycosyloxybenzopyran derivative and antiallergic agent
03/15/2000CN1050293C Ant compsn. preparation and its preparing method
03/15/2000CN1050283C Gel-type cosmetic composite
03/14/2000US6037470 Purine compounds having PDE IV inhibitory activity and methods of synthesis
03/14/2000US6037386 Latex barrier having polymer matrix comprising zinc oxide or zinc gluconate gel irritant deactivating agent; condoms, gloves
03/14/2000US6037377 Antiinflammatory agents and antiallergens
03/14/2000US6037373 Treating nervous system, cytological, hormonal, gastrointestinal and liver disorders
03/14/2000US6037355 Imidazole lipoxygenase inhibitors
03/14/2000US6037146 CDNA clone HE8CH90 that encodes a novel 7-transmembrane receptor
03/14/2000US6036957 Immunology suppression with cd4 and t-cells reactive with mylin protein
03/14/2000US6036956 Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
03/14/2000US6036954 Polypeptides with sequence
03/14/2000CA2282147A1 Immunosuppresive agents
03/14/2000CA2143335C Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
03/14/2000CA2010177C Purified mite allergen
03/09/2000WO2000012738A1 Targeted adenovirus vectors for delivery of heterologous genes
03/09/2000WO2000012737A1 Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
03/09/2000WO2000012706A1 Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
03/09/2000WO2000012703A2 Protein transport-associated molecules
03/09/2000WO2000012688A1 Ehrlichia canis 120-kda immunodominant antigenic protein and gene
03/09/2000WO2000012686A1 Expression systems for functional nucleic acid expression
03/09/2000WO2000012678A2 Staphylococcus aureus genes and polypeptides
03/09/2000WO2000012519A1 Phosphoepoxides, method for making same and uses
03/09/2000WO2000012516A1 Phosphohalohydrins, method for making same and uses
03/09/2000WO2000012514A1 Novel compounds
03/09/2000WO2000012485A1 Pyrimidine compounds
03/09/2000WO2000012483A1 Triptolide prodrugs having high aqueous solubility
03/09/2000WO2000012467A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
03/09/2000WO2000012175A2 Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
03/09/2000WO2000012138A2 Cells expressing immunoregulatory molecules and uses therefor
03/09/2000WO2000012131A1 Multicomponent vaccines
03/09/2000WO2000012130A1 Rp105 agonists and antagonists
03/09/2000WO2000012129A2 Salmonella typhi vaccine compositions
03/09/2000WO2000012126A1 Autoantibody inhibitors
03/09/2000WO2000012125A1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
03/09/2000WO2000012124A1 Oral vaccine compositions
03/09/2000WO2000012121A1 Method of dna vaccination
03/09/2000WO2000012120A1 A pharmaceutical composition containing calcineurin b subunit
03/09/2000WO2000012111A2 Selective treatment of endothelial somatostatin receptors
03/09/2000WO2000012107A1 Composition containing pyrrolizidine-alkaloid-free petasites
03/09/2000WO2000012106A1 Gabab1aa receptor
03/09/2000WO2000012105A1 RAMP2a: RECEPTOR ACTIVITY MODIFYING PROTEIN-2a
03/09/2000WO2000012085A1 Ascorbate-isoquercetin compositions
03/09/2000WO2000012084A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000WO2000012076A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
03/09/2000WO2000012072A2 The use of fumaric acid derivatives in transplant medicine
03/09/2000WO2000012067A1 Novel pharmaceutical salt form
03/09/2000WO1999065516A8 Methods and compositions for treating diseases mediated by transglutaminase activity
03/09/2000WO1999064570A9 Novel methods and interferon deficient substrates for the propagation of viruses
03/09/2000WO1999064068A9 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
03/09/2000WO1999060013A3 Il-6 antagonist peptides
03/09/2000WO1999055873A3 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
03/09/2000WO1999051215A3 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
03/09/2000WO1999020260A3 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
03/09/2000DE19839566A1 Verwendung von Fumarsäurederivaten in der Transplantationsmedizin Use of fumaric acid derivatives in transplantation
03/09/2000CA2777661A1 Multicomponent vaccines
03/09/2000CA2731995A1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
03/09/2000CA2514899A1 Method of modulating memory effector t-cells and compositions
03/09/2000CA2342901A1 Triptolide prodrugs having high aqueous solubility
03/09/2000CA2342222A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000CA2341755A1 Cells expressing immunoregulatory molecules and uses therefor
03/09/2000CA2341703A1 Salmonella typhi vaccine compositions
03/09/2000CA2341578A1 Phosphoepoxides, method for making same and uses
03/09/2000CA2341544A1 Method of dna vaccination
03/09/2000CA2341522A1 Novel pharmaceutical salt form
03/09/2000CA2341352A1 Oral vaccine compositions
03/09/2000CA2341311A1 Staphylococcus aureus genes and polypeptides
03/09/2000CA2341061A1 Targeted adenovirus vectors for delivery of heterologous genes
1 ... 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 ... 1172